- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03977922
A Pilot Nutrition Program for Spinal Cord Injury and MS
A Pilot Nutrition Program for Spinal Cord Injury and MS: Effects on Inflammation, Cardiometabolic Health and Psychosocial Well-being
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Spinal cord injury (SCI) and multiple sclerosis (MS) are both conditions characterized by chronic inflammation as indicated by elevated levels of circulating pro-inflammatory cytokines. These cytokines can have a wide array of negative impacts in the body. For example, pro-inflammatory cytokines can impair serotonin production and usage in the brain and thus increase the risk of depression. Likewise, they can sensitize nociceptors and increase the intensity and frequency of neuropathic pain. Recent work has shown that a 3-month anti-inflammatory diet is not only effective in reducing pro-inflammatory cytokines, but also reduced self-reported depression and neuropathic pain, by approximately 55% and 40%, respectively (Allison and Ditor, 2015; Allison et al., 2016). These data are very promising since both depression and neuropathic pain are highly prevalent after SCI and MS, and current pharmacological treatments are only partially effective and associated with unwanted side-effects.
Despite the highly encouraging results mentioned above, one year following the conclusion of the study participants were no longer adhering to the anti-inflammatory diet. Specifically, during the actual study, adherence to the diet was, on average 89% (70-100%), while at one-year follow-up, adherence fell to, on average 43% (36-53%), which was virtually the same as baseline eating habits (Allison and Ditor, 2018). Likewise, measures of depression went back to baseline as well. These follow-up data prompted a subsequent qualitative study in which former participants were interviewed as a means to identify the facilitators and barriers that affect one's ability to adhere to the anti-inflammatory diet (Bailey et al., 2018). This qualitative study is now being used to inform a nutrition program that is in the early stages of development at a wheelchair accessible exercise facility; Power Cord.
The nutrition program will consist of 4 aspects:
- Once per week (Monday mornings), nutrition program members will come to Power Cord to pick up their box of ingredients for their meals that week (Monday to Friday). Recipe cards will accompany the ingredients, and enough food will be provided for 3 meals and 2 snacks per day. The meals will be based on the anti-inflammatory diet mentioned above. The nutrition program will not provide ingredients for Saturdays and Sundays, for three reasons. First, research has shown that occasional "cheat meals" help with long term compliance to the diet. Second, members should eventually become self-sufficient and even wean themselves off the nutrition program (or reduce their involvement). Third, this reduces the cost of the program and will help with long term sustainability.
- To assist the members with meal preparation, there will also be 10-12 online videos that cover basic kitchen/cooking skills, how to prepare the meals in the program, how to shop for healthy foods at the grocery store, etc.
- At the beginning of the program each member will be provided with a few pieces of accessible kitchen equipment that will made food preparation and cooking much easier. The equipment includes, a 1 Second Slicer (to be used in place of a knife), a padded lap tray (to be used as a cutting surface on the lap instead of a counter), a toaster oven, light weight pots and pans, a Nutri Bullet Blender.
- Once per month, there will be a live cooking class.
Before this nutrition program can be long-term and sustainable, a 12-week pilot program will be completed to help determine the eventual membership pricing and feasibility. This pilot will also be used to determine the effects of the diet on body composition, inflammation, neuropathic pain, depression and quality of life. This pilot program will include 15 existing Power Cord members; 5 with SCI and 5 with MS who will be in the diet group, and 5 individuals with SCI and MS who will serve as controls. Participants in the pilot program will only pay $100/month for their involvement, and this will include their kitchen equipment, food for the 3-months, cooking classes and access to online content. The study and outcome measures described in this posting pertain to the 3-month pilot nutrition program.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Saint Catharines, Ontario, Canada, L2S 3A1
- Brock University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals with spinal cord injury may be of any level of injury (paraplegia/tetraplegia) and severity of injury (complete/incomplete) and will be at least one year post-injury.
- Individuals with MS will have a diagnosis of relapsing remitting MS or secondary progressive MS, and will be at least one year post-diagnosis.
Exclusion Criteria:
- . Participants will be asymptomatic for pressure ulcers, urinary tract infections or respiratory infections at the time of recruitment, and they may be recreationally active but those participating in elite or high-level athletics/training will be excluded from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Diet group
The diet group will be involved in a 12-week pilot nutrition program based on the anti-inflammatory diet studied by Allison and Ditor (2015). The nutrition program will entail:
|
The diet group will be involved in a 12-week pilot nutrition program that will be based on the anti-inflammatory diet previously studied by Allison and Ditor (2015).
|
|
NO_INTERVENTION: Control group
The control group will eat their usual diet for the 12-week period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline body composition at 12 weeks
Time Frame: Before and after the 12-week nutrition program (in both groups)
|
Dual-energy x-ray absorptiometry (DEXA) to measure the percentage of body fat.
|
Before and after the 12-week nutrition program (in both groups)
|
|
Change from baseline inflammation at 12 weeks
Time Frame: Before and after the 12-week nutrition program (in both groups)
|
Blood samples will be analyzed for various inflammatory mediators
|
Before and after the 12-week nutrition program (in both groups)
|
|
Change from baseline neuropathic pain at 12 weeks
Time Frame: Before and after the 12-week nutrition program (in both groups)
|
The Neuropathic pain questionnaire will be used to determine self-reported neuropathic pain
|
Before and after the 12-week nutrition program (in both groups)
|
|
Change from baseline depression at 12 weeks
Time Frame: Before and after the 12-week nutrition program (in both groups)
|
The Center for Epidemiological Studies Depression scale (CES-D) will be used to determine self-reported depression.
This scale ranges from 0 to 60 with higher scored indicating more depression.
|
Before and after the 12-week nutrition program (in both groups)
|
|
Change from baseline perceived quality of Life at 12 weeks
Time Frame: Before and after the 12-week nutrition program (in both groups)
|
The Perceived Quality of Life questionnaire (PQOL) will be used to determine self-reported quality of life
|
Before and after the 12-week nutrition program (in both groups)
|
|
Change from baseline blood lipids at 12 weeks
Time Frame: Before and after the 12-week nutrition program (in both groups)
|
Blood samples will be analyzed for blood lipids
|
Before and after the 12-week nutrition program (in both groups)
|
|
Change from baseline glucose tolerance at 12 weeks
Time Frame: Before and after the 12-week nutrition program (in both groups)
|
Blood samples will be analyzed for HbA1c
|
Before and after the 12-week nutrition program (in both groups)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dietary intake
Time Frame: At baseline, and after 4 weeks, 8 weeks and 12 weeks (in both groups)
|
Food logs will be collected to determine adherence to the dietary intake during the 12-week study for both groups.
|
At baseline, and after 4 weeks, 8 weeks and 12 weeks (in both groups)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David S Ditor, PhD, Brock University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Trauma, Nervous System
- Spinal Cord Diseases
- Multiple Sclerosis
- Wounds and Injuries
- Spinal Cord Injuries
Other Study ID Numbers
- 18-309 - Ditor
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Diet group
-
Daewoong Pharmaceutical Co. LTD.CompletedIdiopathic Pulmonary FibrosisKorea, Republic of
-
University of CreteCompletedObstructive Sleep Apnoea | Hypopnoea SyndromeGreece
-
University Hospital TuebingenRecruiting
-
Instituto Tecnológico y de Estudios Superiores...University of Guadalajara; Instituto Tecnológico de TepicCompletedDyslipidemias | Overweight and ObesityMexico
-
University of CopenhagenWageningen University and ResearchCompletedDiet, Healthy | Breath AnalysisDenmark
-
Children's Hospital of Fudan UniversityCompleted
-
Akdeniz UniversityNot yet recruitingPeriodontitis (Stage 3) | Periodontitis Stage IVTurkey (Türkiye)
-
Centro di Riferimento per l'Epidemiologia e la...Azienda Sanitaria Locale Torino 1CompletedBreast Cancer | Colorectal Cancer | Lifestyle Risk Reduction | Weight Changes, BodyItaly
-
Rio de Janeiro State UniversityRio de Janeiro State Research Supporting Foundation (FAPERJ)Completed
-
Oslo University HospitalCompletedSmoking | Obesity | OverweightNorway